Held in Lisbon, Portugal, from May 27–29, 2025, the Global Clinical Oncology Conference (GCOC 2025) hosted by the Life and Medical Sciences Innovation Institute (LMSII) showcased cutting-edge innovations in cancer prevention, diagnostics, and treatment. This hybrid event brought together oncology experts across 22 breakout sessions, a plenary forum, and poster exhibits, spotlighting the shift toward precision, accessibility, and digital transformation in global oncology.

  1. Early Detection and Preventive Strategies in High-burden Cancers

Key Development: GCOC 2025 highlighted how non-invasive early detection technologies — particularly for colorectal and pancreatic cancers — are pushing the innovation curve in AI imaging, biosensors, and screening protocols.

Best Practices:  Speakers emphasized AI-based diagnostic imaging and wearable biosensors that can detect early markers in at-risk populations through risk-based screening programs.

Growth Opportunities:

    • Expand wearable and liquid biopsy platforms for early-stage detection.
    • Integrate real-world data and AI for population-based cancer risk stratification.
    • Develop screening tools optimized for use in low-resource, high-burden regions.

Note: These discussions align closely with insights from our latest analysis, Global Oncology Diagnostics in IVD: Growth Opportunities

  1. Precision Oncology: From Genomics to Multi-omics Integration

Key Development: A clear trend emerged in the move beyond genomics toward multi-omics (transcriptomics, proteomics, and metabolomics) for cancer characterization — particularly in breast and GI (gastrointestinal) cancers with high tumor heterogeneity.

Best Practices: Multi-omics platforms offering real-time integration and decision support were highlighted as key enablers for adaptive clinical trials and next-gen companion diagnostics.

Growth Opportunities:

  • Develop cloud-based platforms that support multi-omics data integration.
  • Partner with pharma companies for adaptive trials and companion diagnostics (CDx) development.
  • Position technologies to overcome tumor heterogeneity and treatment resistance.

Note: These discussions align closely with insights from our latest analyses, Precision Oncology Market Trends and Growth Opportunities and Companion Diagnostics (CDx): Technology Innovation and Growth Opportunities

  1. Biomarker Co-Development as Both Bottleneck and Opportunity

Key Development: The absence of validated biomarker endpoints in early-phase trials is delaying regulatory progress — but also opening doors for specialized diagnostic partnerships.

Best Practices: Predictive and prognostic biomarkers are now pivotal in immuno-oncology (IO) and targeted therapy trials. Strategic partnerships are emerging between biotech, contract research organizations (CROs), and AI companies focused on tissue and digital biomarkers.

Growth Opportunities:

  • Build AI-powered pathology tools for spatial biomarker validation in GI and IO cancers.
  • Offer external biomarker discovery pipelines to reduce trial delays.
  • Develop imaging + tissue biomarker co-validation platforms.

Note: These discussions align closely with insights from our latest analysis, Next-Gen Cell Therapies and Precision Immunotherapies

  1. Digital and AI-Enabled Platforms are Revolutionizing Oncology

Key Development: Digital transformation is becoming inseparable from modern oncology. GCOC 2025 showcased AI tools for pathology, radiomics, and decision support reshaping diagnostics and care delivery.

Best Practices: Both large companies and startups are expanding their digital pathology and AI portfolios to support scalable, data-driven oncology care.

Growth Opportunities:

  • Develop AI analytics engines tailored to radiology-pathology convergence.
  • Expand digital pathology for global use in decentralized trial settings.
  • Collaborate with hospitals to integrate AI into clinical workflows.

Note: These discussions align closely with insights from our latest analysis, Digital Pathology: Technology Innovations and Growth Trends

  1. Decentralized Trials and Inclusive Access Models Are Redefining the Pipeline

Key Development: A shift toward digitally enabled, decentralized clinical trials is making global inclusivity more achievable, particularly in underrepresented regions.

Best Practices: Startups enabling virtual consent, remote diagnostics, and biospecimen collection are gaining visibility and investor attention.

Growth Opportunities:

  • Deploy virtual trial platforms in low-infrastructure regions (Africa, Southeast Asia).
  • Innovate remote consent and biospecimen handling systems.
  • Partner with NGOs and health agencies for global outreach.

Note: These discussions align closely with insights from our latest analysis, Decentralized Testing Models in Clinical Diagnostics

Looking Ahead: Key Oncology Priorities from GCOC 2025

At GCOC 2025, a forward-looking consensus emerged around accelerating innovation in oncology diagnostics, trials, and equitable access. The following short-, mid-, and long-term focus areas reflect strategic priorities for stakeholders shaping the future of cancer care:

Short-term (1 year):

  • Operationalize multi-omics diagnostics into clinical workflows for breast, GI, and lung cancers.
  • Expand decentralized and digitally enabled trial infrastructures to reduce recruitment delays and ensure geographic diversity.
  • Invest in AI-powered pathology and imaging tools for early cancer detection, especially in underserved regions.

Mid-term (2–3 years):

  • Advance biomarker co-development ecosystems by strengthening pharma-diagnostics partnerships and CRO collaborations.
  • Scale up wearable and non-invasive biosensor integration for at-home patient monitoring and recurrence detection.
  • Embed real-time clinical decision support platforms to improve personalized treatment planning and trial matching.

Long-term (5+ years):

  • Achieve globally accessible oncology diagnostics through affordable point-of-care innovations and remote biospecimen workflows.
  • Unlock curative potential in cancer care by integrating precision immunotherapies, AI analytics, and digital twins.
  • Redefine oncology R&D models via adaptive platform trials and real-world evidence frameworks to accelerate approvals and reduce disparities.

What role will your organization play in making precision oncology truly global, accessible, and equitable by 2030?

What’s your next move?

Appendix:

Explore Frost & Sullivan’s latest analyses on oncology innovation:

Your Transformational Growth Journey Starts Here

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form

Schedule Your Growth Dialog™

Engage in a Growth Dialog
Become a Member of Growth Council
Join Companies to Action Program
Enlist as a Frost Growth Expert
Terms*
This field is for validation purposes and should be left unchanged.

Share This